Table 2. Baseline Characteristics.
| Characteristic | No. (%) | ||
|---|---|---|---|
| Etanercept | Adalimumab | Ustekinumab | |
| Total, No. | 1509 | 4000 | 1627 |
| Age, median (IQR), y | 45 (36-54) | 45 (36-54) | 46 (37-55) |
| Females | 635 (42) | 1645 (41) | 644 (40) |
| Disease duration, median (IQR), y | 21 (13-30) | 21 (13-30) | 21 (12-31) |
| Missing | 12 (1) | 50 (1) | 13 (1) |
| BMI, median (IQR) | 29 (26-34) | 30 (26-34) | 31 (27-36) |
| Missing | 120 (8) | 278 (7) | 134 (8) |
| Baseline PASI, median (IQR) | 14 (11-19) | 14 (11-19) | 15 (11-20) |
| 6 mo PASI, median (IQR) | 4 (2-8) | 2 (0-5) | 2 (0-6) |
| Missing | 558 (37) | 1571 (39) | 649 (40) |
| 12 mo PASI, median (IQR) | 4 (2-7) | 2 (0-5) | 2 (0-4) |
| Missing | 533 (35) | 1482 (37) | 649 (40) |
| Age ≥70 y | 60 (4) | 109 (3) | 68 (4) |
| Disease duration >10 y | 1272 (84) | 3392 (85) | 1375 (85) |
| Concomitant therapy | 280 (19) | 645 (16) | 197 (12) |
| Registration dosea | 977 (65) | 3329 (83) | 859 (53) |
| Missing | 263 (17) | 687 (17) | 239 (15) |
| Biologic-naïve | 1386 (92) | 3372 (84) | 1037 (64) |
| Baseline PsA | 349 (23) | 963 (24) | 329 (20) |
| ≥3 Comorbidities | 107 (7) | 247 (6) | 148 (9) |
| Ever smoked | 772 (51) | 2280 (57) | 1016 (62) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); i-PASI, insufficient baseline Psoriasis Area and Severity Index; m-PASI, missing baseline PASI; PsA, psoriatic arthritis.
a
Doses reported are etanercept, 50 mg weekly; adalimumab, 40 mg fortnightly; and ustekinumab, 45 mg 12 weekly after loading schedules were complete.